The purpose of this study is to assess how the body handles Abemaciclib when it is given with
another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib
that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from
the body. The safety and tolerability of these drugs will be studied.
Each participant will complete 2 study periods in fixed order. After screening, Period 1 will
last approximately 8 days and Period 2 will last approximately 15 days. Participants who
complete Period 2 may continue to receive Abemaciclib in 28-day cycles until discontinuation
criteria are met.